InnoCan Pharma (TSE:INNO)
:INNO
Want to see TSE:INNO full AI Analyst Report?
Top Page
InnoCan Pharma
(INNO)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$3.00
▼(-60.00% Downside)
Action:Reiterated
Date:05/29/26
The score is held down primarily by weak financial performance (ongoing losses, slowing TTM revenue, and negative operating/free cash flow) and bearish technicals (below major moving averages with negative MACD). A moderate balance sheet provides some support, but valuation is also pressured due to a negative P/E and no dividend yield data.
Positive Factors
High Gross Margin
A ~90% gross margin indicates the business generates sizable markup on product costs, giving structural operating leverage. If management contains SG&A and R&D growth, these margins can convert to durable operating profit over 2–6 months as sales scale or cost discipline continues.
Negative Factors
Negative Cash Flow / Cash Burn
TTM negative operating and free cash flow signal inconsistent cash generation and resumed cash burn after 2025. This erodes runway, forces external financing or dilution risk, and constrains the firm’s ability to invest in commercialization or trials without additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A ~90% gross margin indicates the business generates sizable markup on product costs, giving structural operating leverage. If management contains SG&A and R&D growth, these margins can convert to durable operating profit over 2–6 months as sales scale or cost discipline continues.
Read all positive factors
InnoCan Pharma (INNO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$13.05M
Dividend YieldN/A
Average Volume (3M)920.00
Price to Earnings (P/E)―
Beta (1Y)-0.60
Revenue Growth-17.50%
EPS Growth-120.67%
CountryCA
Employees11
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume392
30 Day Avg. Volume920
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InnoCan Pharma Business Overview & Revenue Model
Company Description
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Pol...
How the Company Makes Money
null...
InnoCan Pharma Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
62
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.18M | 26.61M | 29.44M | 13.66M | 2.56M | 196.00K |
| Gross Profit | 22.61M | 23.93M | 26.19M | 11.98M | 2.11M | 121.00K |
| EBITDA | -681.25K | 130.00K | 961.00K | -3.77M | -3.85M | -10.04M |
| Net Income | -1.50M | -1.12M | -1.83M | -4.70M | -3.89M | -10.06M |
Balance Sheet | ||||||
| Total Assets | 10.85M | 10.52M | 9.26M | 6.94M | 6.98M | 12.57M |
| Cash, Cash Equivalents and Short-Term Investments | 6.68M | 6.69M | 5.01M | 3.88M | 4.95M | 11.05M |
| Total Debt | 1.42M | 930.00K | 10.00K | 33.00K | 34.00K | 1.00K |
| Total Liabilities | 2.92M | 2.29M | 2.24M | 2.55M | 751.00K | 3.56M |
| Stockholders Equity | 5.21M | 5.60M | 5.17M | 4.10M | 6.39M | 9.05M |
Cash Flow | ||||||
| Free Cash Flow | -381.70K | 479.00K | -1.59M | -3.95M | -6.09M | -6.67M |
| Operating Cash Flow | -370.71K | 495.00K | -1.58M | -3.90M | -6.07M | -6.63M |
| Investing Cash Flow | -12.53K | -15.00K | 54.00K | -84.00K | -31.00K | -48.00K |
| Financing Cash Flow | 578.09K | 1.15M | 2.70M | 2.92M | 125.00K | 15.30M |
InnoCan Pharma Technical Analysis
Negative
7.50
Price Trends
4.84
Negative
5.93
Negative
9.34
Negative
Market Momentum
-0.47
Negative
25.46
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:INNO, the sentiment is Negative. The current price of 7.5 is above the 20-day moving average (MA) of 3.42, above the 50-day MA of 4.84, and below the 200-day MA of 9.34, indicating a bearish trend. The MACD of -0.47 indicates Negative momentum. The RSI at 25.46 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:INNO.
InnoCan Pharma Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | C$29.74M | -3.38 | -19.10% | ― | 0.66% | -14.29% | |
50 Neutral | C$52.83M | -0.76 | -19.76% | ― | -100.00% | 87.93% | |
44 Neutral | C$13.05M | -6.18 | -71.80% | ― | -17.50% | -120.67% | |
41 Neutral | C$18.84M | -5.38 | -256.01% | ― | ― | -28.29% | |
41 Neutral | C$15.47M | -4.25 | -68.32% | ― | 1.96% | -24.60% |
* Consumer Defensive Sector Average
TSE:INNO
InnoCan Pharma
2.90
-11.73
-80.17%
TSE:ATLE
Willow Biosciences Inc
0.14
-0.18
-55.56%
TSE:QNTM
Quantum Biopharma
5.70
-31.30
-84.59%
TSE:LABS
MediPharm Labs
0.07
>-0.01
-6.67%
TSE:VM
Voyageur Pharmaceuticals
0.11
-0.14
-56.25%
TSE:AVCN
Avicanna
0.13
-0.14
-50.94%
InnoCan Pharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Innocan Pharma Secures Additional Insider Debenture Ahead of Planned U.S. Offering
Positive
Apr 6, 2026
Innocan Pharma has closed an additional US$200,000 secured debenture financing with its largest shareholder, Tamar Innovest Ltd., following a prior US$450,000 debenture completed in March 2026. The new debenture bears 10% annual interest and will ...
Business Operations and StrategyPrivate Placements and Financing
Innocan Pharma Secures Additional Insider Debenture Financing Ahead of Planned U.S. Offering
Positive
Mar 31, 2026
Innocan Pharma plans to issue an additional US$200,000 debenture to its largest shareholder, Tamar Innovest, following a prior US$450,000 debenture earlier in March, with both instruments carrying a 10% annual interest rate and secured under an ex...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.